SEC Form 4 · accession 0001144204-17-021384
PLx Pharma Inc. · PLXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J Valentino
Officer — Executive Chairman · Director
Period of report
Apr 19, 2017
Accepted (ET)
Apr 20, 2017 · 9:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001497504
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 19, 2017 | A | 93,295 | — | A | 93,295 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionsF2,F3 | $12.44 | Apr 19, 2017 | A | 112,509 | A | — | Jul 22, 2025 | Common Stock | 112,509 | 112,509 | D |
Explanation of responses
- F1Received in exchange for 118,461 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.).
- F2Received in connection with the Merger in exchange for an employee stock option to buy 142,857 shares of PLx Opco Inc. common stock for $9.80 per share.
- F3The option is exercisable as to 60,005 shares as of the date hereof, and will become exercisable as to an additional 26,252 shares on each of July 22, 2017 and July 22, 2018 (generally subject to continued employment or consulting relationship through such date).